DOCSLIB.ORG

TLR9 Agonist MGN1703 Enhances B Cell Differentiation and Function in Lymph Nodes Mariane H

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TLR9 Agonist MGN1703 Enhances B Cell Differentiation and Function in Lymph Nodes Mariane H University of Nebraska at Omaha DigitalCommons@UNO Biology Faculty Publications Department of Biology 7-2019 TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes Mariane H. Schleimann Aarhus University Maria-Louise Kobberø Aarhus University Line K. Vibholm Aarhus University Katherine Kjær Aarhus University Leila B. Giron The Wistar Institute See next page for additional authors Follow this and additional works at: https://digitalcommons.unomaha.edu/biofacpub Part of the Biology Commons Recommended Citation Schleimann, Mariane H.; Kobberø, Maria-Louise; Vibholm, Line K.; Kjær, Katherine; Giron, Leila B.; Busman-Sahay, Kathleen; Chan, Chi Ngai; Nekorchuk, Michael; Schmidt, Manuel; Wittig, Burghardt; Damsgaard, Tine E.; Ahlburg, Peter; Hellfritzsch, Michel B.; Zuwala, Kaja; Rothemejer, Frederik H.; Olesen, Rikke; Schommers, Phillipp; Klein, Florian; Dweep, Harsh; Kossenkov, Andrew; Nyengaard, Jens R.; Estes, Jacob D.; Abdel-Mohsen, Mohamed; Østergaard, Lars; Søgaard, Ole S.; and Denton, Paul W., "TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes" (2019). Biology Faculty Publications. 129. https://digitalcommons.unomaha.edu/biofacpub/129 This Article is brought to you for free and open access by the Department of Biology at DigitalCommons@UNO. It has been accepted for inclusion in Biology Faculty Publications by an authorized administrator of DigitalCommons@UNO. For more information, please contact [email protected]. Authors Mariane H. Schleimann, Maria-Louise Kobberø, Line K. Vibholm, Katherine Kjær, Leila B. Giron, Kathleen Busman-Sahay, Chi Ngai Chan, Michael Nekorchuk, Manuel Schmidt, Burghardt Wittig, Tine E. Damsgaard, Peter Ahlburg, Michel B. Hellfritzsch, Kaja Zuwala, Frederik H. Rothemejer, Rikke Olesen, Phillipp Schommers, Florian Klein, Harsh Dweep, Andrew Kossenkov, Jens R. Nyengaard, Jacob D. Estes, Mohamed Abdel-Mohsen, Lars Østergaard, Ole S. Søgaard, and Paul W. Denton This article is available at DigitalCommons@UNO: https://digitalcommons.unomaha.edu/biofacpub/129 EBioMedicine 45 (2019) 328–340 Contents lists available at ScienceDirect EBioMedicine journal homepage: www.ebiomedicine.com TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes Mariane H. Schleimann a,b,⁎, Maria-Louise Kobberø c,LineK.Vibholma,c,KathrineKjæra,c, Leila B. Giron d, Kathleen Busman-Sahay b, Chi Ngai Chan b, Michael Nekorchuk b,ManuelSchmidte, Burghardt Wittig e,f,1, Tine E. Damsgaard c,g,PeterAhlburgh, Michel B. Hellfritzsch c,i, Kaja Zuwala a,c, Frederik H. Rothemejer c, Rikke Olesen c,PhillippSchommersj,k,l, Florian Klein j,l, Harsh Dweep m, Andrew Kossenkov m, Jens R. Nyengaard c,n, Jacob D. Estes b, Mohamed Abdel-Mohsen d,LarsØstergaarda,c, Martin Tolstrup a,c, Ole S. Søgaard a,c,PaulW.Dentona,c,⁎⁎ a Department of Infectious Diseases, Aarhus University Hospital, Denmark b Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, USA c Department of Clinical Medicine, Aarhus University, Denmark d Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA e Mologen AG, Berlin, Germany f MolBio2Math - Molecular Biology & Integral Biomathics, a non-profit Foundation Institute, Berlin, Germany g Department of Plastic and Breast Surgery, Plastic Surgery Research Unit, Aarhus University Hospital, Denmark h Department of Anesthesiology, Aarhus University Hospital, Denmark i Department of Radiology, Aarhus University Hospital, Denmark j Institute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany k Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany l German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany m Bioinformatics Facility, The Wistar Institute, Philadelphia, PA, USA n Core Centre for Molecular Morphology, Section for Stereology and Microscopy, Department of Clinical Medicine, Centre for Stochastic Geometry and Advanced Bioimaging, Aarhus University Hospital, Aarhus, Denmark article info abstract Article history: Background: TLR9 agonists are being developed as immunotherapy against malignancies and infections. TLR9 is Received 1 May 2019 primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). TLR9 signalling may be critically impor- Received in revised form 27 June 2019 tant for B cell activity in lymph nodes but little is known about the in vivo impact of TLR9 agonism on human Accepted 2 July 2019 lymph node B cells. As a pre-defined sub-study within our clinical trial investigating TLR9 agonist MGN1703 Available online 9 July 2019 (lefitolimod) treatment in the context of developing HIV cure strategies (NCT02443935), we assessed TLR9 agonist-mediated effects in lymph nodes. Keywords: Methods: Participants received MGN1703 for 24 weeks concurrent with antiretroviral therapy. Seven participants HIV cure TLR9 agonist completed the sub-study including lymph node resection at baseline and after 24 weeks of treatment. A variety of B cell differentiation tissue-based immunologic and virologic parameters were assessed. B cell follicle Findings: MGN1703 dosing increased B cell differentiation; activated pDCs, NK cells, and T cells; and induced a Antibody glycosylation robust interferon response in lymph nodes. Expression of Activation-Induced cytidine Deaminase, an essential regulator of B cell diversification and somatic hypermutation, was highly elevated. During MGN1703 treatment IgG production increased and antibody glycosylation patterns were changed. Interpretation: Our data present novel evidence that the TLR9 agonist MGN1703 modulates human lymph node B cells in vivo. These findings warrant further considerations in the development of TLR9 agonists as immunother- apy against cancers and infectious diseases. ⁎ Correspondence to: M. H. Schleimann, Postdoc at Research Department of Infectious Diseases, Aarhus University Hospital, Skejby, Palle Juul Jensens Boulevard 99, 8200 Aarhus, Denmark. ⁎⁎ Correspondence to: P. W. Denton University of Nebraska at Omaha, Allwine Hall 109B, 6001 Dodge Street, Omaha, NE 68182-0040, USA. E-mail addresses: [email protected] (M.H. Schleimann), [email protected] (P.W. Denton). 1 Senior advisor to Mologen AG, Berlin, Germany. https://doi.org/10.1016/j.ebiom.2019.07.005 2352-3964/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). M.H. Schleimann et al. / EBioMedicine 45 (2019) 328–340 329 Fund: This work was supported by Aarhus University Research Foundation, the Danish Council for Independent Research and the NovoNordisk Foundation. Mologen AG provided study drug free of charge. © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/). 1. Introduction stimulation in human pDCs are well described ex vivo and in vivo [1–8]. In short, TLR9 stimulated pDCs produce interferon α (IFN-α). Pattern recognition receptors are innate molecules that sense This type I interferon production leads to a stimulatory environment pathogen-associated or danger-associated molecular patterns [1]. One that results in T, NKT, and NK cells becoming activated with improved such receptor, the toll-like receptor 9 (TLR9), is found primarily in capacity for cytotoxic effector functions. Since engaging TLR9 leads to endosomes of plasmacytoid dendritic cells (pDCs) and B cells where it heightened activity of immune effector cells, the development of TLR9 detects non-methylated cytosine-guanine (CpG) DNA motifs [2,3]. agonists as immunotherapy for cancers and infectious diseases is a These dinucleotide motifs are frequently found in bacterial DNA as field of intense research. well as in transformed cells [1–4]. The downstream effects of TLR9 TLR9 agonists include multiple classes of CpG DNA oligonucleo- tides (CpG ODNs) as well as members of the double stem loop immu- nomodulator (dSLIM) class of molecules [2,4]. CpG ODNs are linear DNA fragments that harbor CpG motifs and these fragments are typ- fi Research in context ically protected from nuclease degradation by a modi ed phospho- rothioate backbone. To avoid chemical modification leading to unwanted side effects, the dSLIM molecules utilize a covalently- Evidence before this study closed dumbbell-shaped configuration offering protection from nucleases. Because the major effects of TLR9 stimulation occur in Synthetic TLR9 agonists are being developed as immunotherapy lymphoid tissue, we need to study this specific anatomical compart- for the treatment of cancers and chronic infections as well as vac- ment to fully understand how TLR9 agonists engage the immune sys- cine adjuvants. Few human PBMC in vitro or murine in vivo studies tem. Such investigations provide profound insights into how have examined the direct effect of TLR9 agonists on B cells. Al- responses to TLR9 agonism differ between anatomical compart- though the analyses utilized in these studies were not designed ments. For example, we previously reported compartmentalized for in depth interrogation of B cells, they indicated that B cell pro- human intestinal responses to MGN1703 (lefitolimod; a member of liferation and differentiation are stimulated by TLR9 agonism. the dSLIM class of TLR9 agonists [4,9–11]) dosing that were quite nu- However, no previous studies have investigated the in
Load more

Recommended publications
  • PDF-Download
    2018 Facts & Trends 6th Analysis of European Biotech Companies on the Stock Markets: US versus Europe Destination Growth www.biocom.de CONSULTANCY & RESEARCH © BIOCOM AG, Berlin 2018 Analysis of European Biotech Companies As a leading information specialist for biotechnology and life sciences in on the Stock Markets: US versus Europe Facts & Trends, 2018 Europe, BIOCOM has extensive knowledge and thirty years of experi- www.biocom.de/en/analysis2018 ence, from basic research to the market. We are active in media, events Editorial Team and services. We offer a broad spectrum of services to our clients from Sandra Wirsching, Simone Ding, Benjamin Röbig (Production), industry and the public sector: Oliver-Sven Reblin (Layout) Publisher BIOCOM AG, Lützowstr. 33–36, 10785 Berlin, Germany Customised consultancy services Tel. +49 30 26 49 21-0, Fax +49 30 26 49 21-11, Surveys and market intelligence [email protected], www.biocom.de Sandra Wirsching OECD data collections in biotechnology and life sciences Picture Credits Division Manager xubingruo/istockphoto.com (Title), peshkov/istockphoto.com (p. 6), Eisenhans/fotolia.com (p. 12), alzay/istockphoto.com (p. 16), Euronext (p. 20), BIOCOM AG A highly qualified team addresses each specific question in depth and Skywalker_II/istockphoto.com (p. 26), Eisenhans/fotolia.com (p. 38) Lützowstr. 33–36 formulates concise answers. If you are interested in more information, 10785 Berlin All material published in this study is protected by copyright. No text or part please visit: thereof may be reproduced in any way or processed, copied and proliferated by +49 30 26 49 21-63 electronic means without prior written consent of the publisher.
    [Show full text]
  • Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate
    Clinical Infectious Diseases Head1=Head2=Head1=Head2/Head1 MAJOR ARTICLE Head2=Head3=Head2=Head3/Head2 Head1_First=Head2=Head1_First=Head2/Head1 NList_dot_numeric2=NList_lc_dot_alpha_Sub1=NList_dot_ numeric=NList_lc_dot_alpha_Sub Short-Course Toll-Like Receptor 9 Agonist Treatment App_Head1=App_Head2=App_Head1=App_Head2/Head1 Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection Line Vibholm,1,2,a Mariane H. Schleimann,1,2,a Jesper F. Højen,1,2 Thomas Benfield,3 Rasmus Offersen,1,2 Katrine Rasmussen,1 Rikke Olesen,1 Anders Dige,2,4 Jørgen Agnholt,2,4 Judith Grau,5 Maria Buzon,5 Burghardt Wittig,6 Mathias Lichterfeld,7 Andreas Munk Petersen,8,9 Xutao Deng,10,11 Mohamed Abdel-Mohsen,10,11,12 Satish K. Pillai,10,11 Sofie Rutsaert,13 Wim Trypsteen,13 Ward De Spiegelaere,13,14 Linos Vandekerchove,13 Lars Østergaard,1,2 Thomas A. Rasmussen,1 Paul W. Denton,1,2 Martin Tolstrup,1,2 and Ole S. Søgaard1,2 1Department of Infectious Diseases, Aarhus University Hospital, 2Institute of Clinical Medicine, Aarhus University, 3Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, and 4Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark; 5Hebron Institute of Research, Department of Infectious Diseases, Barcelona, Spain; 6Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet, Berlin, Germany; 7Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston; Departments of 8Gastroenterology and 9Microbiology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; 10Blood Systems Research Institute, San Francisco, California, and 11University of California, San Francisco; 12The Wistar Institute, Philadelphia, Pennsylvania; and Departments of 13Internal Medicine; and 14Morphology, Faculty of Veterinary Medicine, Ghent University, Belgium (See the Editorial Commentary by Cyktor and Mellors on pages 1696–8.) Background.
    [Show full text]
  • Annual Report Key Data According to IFRS
    ANNUAL REPORT KEY Data according to IFRS in million € 2009 2008 2007 Results Revenues 0.1 0.2 0.2 Personnel expenses 2.2 2.1 3.3 (1) EBIT -6.4 -6.3 -6.8 (1) Net loss for the year -6.3 -6.1 -6.5 (1) R + D expenses 4.8 4.4 4.1 EPS in € ( basic ) -0.64 -0.65 -0.71 (1) Statement of financial position Cash and cash equivalents 6.2 3.3 8.0 Non-current assets 1.9 2.2 2.7 Current assets 6.7 3.8 8.6 Non-current liabilities 0.0 0.0 0.2 Current liabilities 1.1 0.8 0.6 Equity 7.4 5.2 10.5 Equity ratio 86 % 86 % 93 % Cash flow statement Cash flows from operating activities -5.1 -5.0 -5.2 Cash flows from investing activities 0.0 0.0 1.0 Cash flows from financing activities 8.1 0.3 5.8 Number of employees as of Dec. 31 44 44 44 MOLOGEN share Outstanding shares as of Dec. 31 10,143,348 9,378,348 9,316,848 Year end price in € 7.38 6.30 6.70 (1) Figures have been adjusted according to IAS 8.42 Please refer to the annual report 2008. MOLOGEN AG INDEX TO THE SHAREHOLDERS separate ANNUAL FINANCIAL statements 6 LETTER FROM THE BOARD OF directors 50 IFRS Statement OF FINANCIAL POSITION 10 Report OF THE SUPERVisory BOARD 51 IFRS statement OF COMPREHENSIVE INCOME 14 THE MOLOGEN SHARE IN 2009 52 IFRS Statement OF CASH FLOWS 53 IFRS statement OF CHANGES IN EQUITY 54 IFRS statement OF CHANGES IN FIXED ASSETS SPECIAL featURE 57 Notes 18 THE FIGHT against CANCER 88 AUditors’ Report 89 RESPONSIBILITY Statement Management Report 25 BUSINESS actiVITY AND strategy 26 LEGAL FRAMEWORK CONDITIONS 26 PERFORMANCE indicators 27 Compensation report 28 Information SUBJECT to SECTION 289 PARA.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 Table of contents 3 Foreword 4 2015 Highlights 6 Working together for great results 14 2015 in numbers 18 Health services 19 Research 20 Learning and teaching 21 Organizational structures 22 Overview of the clinics and institutes 25 Selected publications 2015 Legal notice Publisher Corporate Communications Division, Charité – Universitätsmedizin Berlin Tel. +49 30 450 570 400 | [email protected] | www.charite.de Responsible as per Press Law Uwe Dolderer, Head of Corporate Communications Division Proofing Dr. Julia Biederlack, Christin Dienst, Nancy Janz, Verena Wolff, Manuela Zingl Editing Dr. Katja Furthmann Translations Lingualogic Language Services Design Christine Voigts Zentrale Mediendienstleistungen, Charité – Universitätsmedizin Berlin Photos Wiebke Peitz, Zentrale Mediendienstleistungen, Charité – Universitätsmedizin Berlin Dirk Lässig (page 4, top right; middle right; page 5, middle left; page 9, top right; page 10, top right; page 13, top left), Anne Losemann (page 5, top left), Mestemacher/Agentur Baganz (page 4, middle left), Sabine Gudath (page 4, bottom left; page 5, bottom left), people-photography (page 5, bottom right), Jens Schicke (page 8, top left); Dr. Jan Schmoranzer (page 11, top right), Physikalisch-Technische Bundesanstalt, Marvin Rust (page 12, top left), Ricarda Spiegel (page 12, top right; page 13, top right) Frontispiece: A transparent walkway connects the main ward building in Berlin-Mitte with the rest of the campus (Photo: Sabine Gudath) Foreword 2015 proved to be as extraordinary as it was memorable for Charité – Universitätsmedizin Berlin and its approximately 13,200 staff or 16,850 staff, including subsidiaries. By joining forces to help people in need, Charité staff managed to achieve great results, once again demonstrating that ‚compassion‘ forms an integral part of the organization‘s mission and guides its day-to-day activities.
    [Show full text]
  • PROSPECTUS DATED MARCH 31, 2015 Bookrunner Quirin Bank
    PROSPECTUS DATED MARCH 31, 2015 Prospectus for the public offering in Germany and Luxembourg of 5,657,875 new ordinary bearer shares with no-par value (Stückaktien) from a capital increase against contribution in cash resolved by the Management Board on March 24, 2015, approved by the Supervisory Board on the same day, utilizing the Authorized Capital 2014 as resolved by the ordinary shareholders’ meeting on August 13, 2014 and for admission to trading on the regulated market segment (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) with simultaneous admission to the sub-segment thereof with additional post-admission obligations (Prime Standard) of up to 5,657,875 ordinary bearer shares with no-par value (Stückaktien) from the above mentioned capital increase — each such share with a notional interest in the share capital of €1.00 and full dividend rights from January 1, 2014 — of Mologen AG, Berlin, Germany Subscription price: €5.00 International Securities Identification Number (ISIN): DE0006637200 German Securities Code (Wertpapierkennnummer, WKN): 663720 Trading Symbol: MGN Bookrunner quirin bank CONTENTS Section Page Summary of the Prospectus ................................................................................................................. 1 A – Introduction and Warnings ........................................................................................................ 1 B – Issuer .........................................................................................................................................
    [Show full text]
  • Expression and Evaluation of Medically Relevant Proteins In
    Evaluation of the protozoan parasite L. tarentolae as a eukaryotic expression host in biomedical research Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) Submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Stephan Klatt born in Braunschweig, Germany April 2013 I hereby declare that all experiments and writing contained within this thesis were conducted by myself, all references used are cited accordingly and any personal assistance has been acknowledged by name. All experiments for this thesis were conducted from October 2008 to April 2013 in the group of Dr. Zoltán Konthur at the Department of Vertebrate Genomics under the supervision of Prof. Dr. Hans Lehrach at the Max Planck Institute for Molecular Genetics. 1. Reviewer: Prof. Dr. Hans Lehrach Max Planck Institute for Molecular Genetics Department of Vertebrate Genomics Ihnestraße 63-73 14195 Berlin, Germany 2. Reviewer: Prof. Dr. Burghardt Wittig Freie Universität Berlin Molecular Biology and Bioinformatics Arnimallee 22 14195 Berlin, Germany Date of defence: August 7th 2013 II Acknowledgement I would like to thank Prof. Dr. Hans Lehrach, Director at the Max Planck Institute for Molecular Genetics, for giving me the great opportunity to conduct my dissertation in his department. Furthermore, I thank Prof. Dr. Burghardt Wittig from Freie Universität Berlin for his kindness to serve as an academic advisor of my thesis. First and foremost, I would like to express my sincere gratitude to my direct supervisor Dr. Zoltán Konthur for his continuous support, great tutoring, advice and fruitful discussions as well as for the opportunity to travel, meet and collaborate with international scientists.
    [Show full text]
  • Prof. Dr. Stefan Wölfl SCIENTIFIC VITA 2003
    Prof. Dr. Stefan Wölfl Institute for Pharmacy and Molecular Biotechnology Department of Biology, AG Bioanalytics and Molecular Biology University of Heidelberg 69120 Heidelberg, Germany Phone: +49-(0)6221-54 4878 Fax: +49-(0)6221-56 4884 E-mail: [email protected] SCIENTIFIC VITA 2003 - present Professor Pharmaceutical Biology, Bioanalytics and Molecular Biology, IPMB, Ruprecht-Karls-Universität Heidelberg 2000-2003 Head Research Group Molecular Biology, Klinik für Innere Medizin, Friedrich-Schiller-Universität Jena 1999 Habilitation in Molecular Biology 1998/99 Thüringer-Forschungspreis 1998 1994-2000 Junior Group Leader, Hans-Knöll-Institut für Naturstoffforschung Jena 1990-1994 PostDoc, Massachussets Institute of Technology, Cambridge, USA (Advisor: Alexander Rich) 1986-1990 Graduate Student (PhD in Biochemistry, Advisor: Burghardt Wittig), Freie Universitat Berlin 1984-1985 Practical Year as Pharmacist (Pharmacy and Pharmaceutical Industry; Rosenheim and Herrenberg) 1981-1984 Student of Pharmacy, Freie Universität Berlin 1979-1980 Student of Physics, Ludwig-Maximilians-Universität München COORDINATING FUNCTIONS, OTHER PROFESSIONAL ACTIVITIES 2002-2005 Coordination of clinical projects within the Jena Center for Bioinformatics 2001-2002 Scientific coordinator, construction of new Clinical Research Center Jena 1998 Cofounder: Clondiag Chip Technologies GmbH Jena 1990 Fachapotheker für Offizin Pharamcy 1985-1990 Pharmacist in Public Pharmacy (since 1986 part time) FIELDS OF INTEREST Development of methods for bioanalytics, e.g. micro-array and microsystems technologies; use of chip technologies for diagnostic applications; cellular biosensors for drug testing and environmental analysis, e.g. for identificatin of genotoxic activities; gene regulation in mammalian cells in disease models, e.g. tumor development, and during differentiation; influence of basic biochemical processes on DNA-damage and stress response.
    [Show full text]
  • Doktorarbeit Yuliya Georgieva
    Detection of novel serological biomarkers in two neurodegenerative disorders: Morbus Alzheimer and Multiple Sclerosis Inaugural-Dissertation To obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) Submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Yuliya Georgieva born in Orenburg, Russian Federation Oktober 2013 I hereby declare that all work and writing contained within this thesis was conducted by myself, all used references are cited accordingly and any personal assistance has been acknowledged by name. All work for this thesis was conducted from June 2009 to June 2013 in the working group of Dr. Zoltán Konthur at the Department of Vertebrate Genomics under the supervision of Prof. Dr. Hans Lehrach in the Max Planck Institute for Molecular Genetics. 1. Reviewer: Prof. Dr. Hans Lehrach Max Planck Institute for Molecular Genetics Department of Vertebrate Genomics Ihnestraße 63-73 14195 Berlin, Germany 2. Reviewer: Prof. Dr. Burghardt Wittig Freie Universität Berlin Foundation Institute Molecular Biology and Bioinformatics Arnimallee 22 14195 Berlin, Germany Date of defense: 14.02.2014. Acknowledgment I would like to thank Prof. Dr. Hans Lehrach, Director at the Max Planck Institute for Molecular Genetics, for giving me the great opportunity to conduct my dissertation at his department in such an interesting research area. Furthermore, I thank Prof. Dr. Burghardt Wittig from Freie Universität Berlin for his kindness to serve as an academic advisor of my thesis and for his invaluable advice on this manuscript. I would like to express my sincere gratitude to my direct supervisor Dr. Zoltán Konthur for the support of my dissertation, for his scientific advice, as well as for giving me the opportunity to take part at international conferences and for enabling my voluntary work at btS e.V.
    [Show full text]
  • Z-DNA-Forming Sites Within the Human .3-Globin Gene Cluster
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 780-784, January 1996 Biochemistry Z-DNA-forming sites within the human .3-globin gene cluster (negative supercoiling/transcription rate/erythropoietic cells/topological domain) VERENA MULLER*, MIEKO TAKEYA*, SUSANNE BRENDEL*, BURGHARDT WITTIG*, AND ALEXANDER RICHt *Abteilung Molekularbiologie und Biolnformatik, Institut fur Molekularbiologie und Biochemie, Freie Universitat Berlin, D-14195 Berlin, Germany; and tDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139-4307 Contributed by Alexander Rich, October 2, 1995 ABSTRACT Agarose-encapsulated, metabolically active, MATERIALS AND METHODS permeabilized nuclei from human hematopoietic cell lines in cluster. Cell Culture, Nuclear Preparation, and Z-DNA Sequence were tested for Z-DNA formation the 13-globin gene Isolation. Hematopoietic cell line K-562 [American Type Biotinylated monoclonal antibodies against Z-DNA were dif- Culture Collection (ATCC); CCL 243], K-562/ADM60 and fused into the nuclei and cross-linked to DNA with a 10-ns myelomonocytic U-937 cells (ATCC; CRL 1593) were grown laser exposure at 266 nm. Following digestion with restriction in 90% (vol/vol) RPMI medium 1640/10% (vol/vol) fetal enzymes, fragments that had formed Z-DNA were isolated. bovine serum (Life Technologies, Grand Island, NY) supple- Seventeen regions with Z-DNA sequence motifs in the 73-kb mented with antibiotics. K-562/ADM60 cells were generated region were studied by PCR amplification, and five were found by selecting against adriamycin at 60 ng/ml, resulting in a in the Z conformation. multidrug-resistant phenotype. They were determined to be further differentiated in erythropoietic cell maturation that DNA in the chromatin of eukaryotic cells is not in a static K-562 cells.
    [Show full text]
  • Chromatin from Transcribed Genes Contains HMIG17 Only Downstream from the Starting Point of Transcription
    The EMBO Journal vol.6 no.8 pp.2393-2399, 1987 Chromatin from transcribed genes contains HMIG17 only downstream from the starting point of transcription Tomislav Dorbic and Burghardt Wittig analyzed the DNA with respect to three active genes (Dorbic and Wittig, 1986). In employing this well-defined and highly specific Institut ftir Molekularbiologie und Biochemie, Freie Universitiit Berlin, Amimallee 22, D-1000 Berlin 33, FRG tool we were able to locate HMG17 in the neighbourhood of the transcription starting point of three chicken genes from the re- Communicated by A.Rich spective tissue expressing them. Monoclonal antibodies specific for the non-histone chromo- somal protein HMG17 were used to isolate oligonucleosomes from the transcriptionally active chromatin of chicken liver Results and oviduct. The distribution of HMG17 with respect to the For our analyses the genes for vitellogenin II (active in liver, coding region of three genes was analyzed in these oligo- inactive in oviduct of laying hens), lysozyme and ovalbumin (both nucleosomes by employing two independent experimental active in oviduct, inactive in liver of laying hens) were chosen approaches. In the vitellogenin II gene (active in liver) and (Grez et al., 1981; Bellard et al., 1982; Anderson et al., 1983; the lysozyme and ovalbumin genes (active in oviduct) HMG17 Geiser et al., 1983). From the chromatin containing these three was found only downstream from the respective starting genes nucleosomal material was subjected to indirect immuno- points of transcription. The transition from HMG17-free to precipitation with HMG17-specific antibodies and solid-phase HMG17-containing chromatin is located at the transcription bound protein A (Immuno-Precipitin).
    [Show full text]
  • Visualization of Immune Cells During Toxoplasma Gondii Infection
    Visualization of Immune Cells during Toxoplasma gondii Infection Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaft (Dr. rer. nat.) eingereicht im Fachbereich Biologie, Chemie, Pharmazie der Freien Universität Berlin vorgelegt von Seong-Ji Han geboren in Berlin Januar 2012 1. Gutachterin: Prof. Dr. Ellen Robey University of California, Berkeley Department of Molecular & Cell Biology 142 Life Sciences Addition Berkeley, CA 94720 USA 2. Gutachter: Prof. Dr. Burghardt Wittig Freie Universität Berlin Molecular Biology and Bioinformatics Arnimallee 22 14195 Berlin Germany Disputation am: 25. September. 2012 사랑하는 어머님과 아버님께 감사드리는 마음으로 Mit diesen Worten möchte ich mich bei meinen lieben Goethianern bedanken, die mich seit nun mehr als 23 Jahren in meinem Leben begleitet und unterstützt haben. A special thanks to my mentor Ellen Robey who always supported me through my graduate research and had a large influence in my personal and career development. Further, I would like to thank all Robey lab members, especially Heather Melichar, Janine Coombes, Ena Ladi and Shiao Chan. The Robey lab is the best that could happen to me. Auch geht mein Dank an meine Geschwister, die mich stets bestärkt und an mich geglaubt haben. 진심으로 감사합니다 Vielen, vielen Dank Thanks so much 1. Introduction.............................................................................................................................................. 1 1.1 Toxoplasma gondii......................................................................................................2
    [Show full text]
  • Edison Research Template
    Mologen AG Initiation of coverage Innately adaptive Pharma & biotech Mologen develops anti-cancer immune maintenance therapies aiming to give long- 25 February 2013 lasting responses. The investment case rests on a possible 2013 deal on the lead Price €14.0 project, MGN1703, based on high-quality interim Phase II data. These indicated a Market cap €216m 50% reduction in the hazard risk of disease progression when MGN1703 was dosed every three days. Mologen aims to partner MGN1703 to fund internal development of MGN1601, a cell-based vaccine for metastatic renal cancer. MGN1601 could be an Shares in issue 15.4m orphan drug with no generic version possible; Mologen intends to sell direct. Free float 40% Code MDG Year end Revenue PBT* EPS* DPS P/E Yield (€m) (€m) (c) (c) (x) (%) Primary exchange Frankfurt Prime Standard 12/11 0.14 (6.8) (55.3) 0.0 N/A N/A Other exchanges N/A 12/12e 0.20 (7.2) (51.6) 0.0 N/A N/A 12/13e 0.10 (9.9) (64.5) 0.0 N/A N/A Share price performance 12/14e 0.10 (14.5) (94.4) 0.0 N/A N/A Note: *PBT and EPS are normalised, excluding intangible amortisation and exceptional items. MGN1703 – a clear colorectal cancer maintenance effect MGN1703 is a stable, dumbbell-shaped DNA molecule (dSLIM) that activates innate immunity. Interim data in metastatic colorectal cancer (mCRC) showed that the hazard ratio for disease progression was reduced by 50% compared to a matched placebo group on an intent-to-treat (ITT) basis.
    [Show full text]